Madrigal Pharmaceuticals (NASDAQ:MDGL) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Tuesday.
According to Zacks, “Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-ß agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia and high triglycerides; and MGL-3745, a thyroid hormone receptor-ß agonist which are in pre-clinical trial stage. Madrigal Pharmaceuticals Inc., formerly known as Synta Pharmaceuticals Corp., is based in Fort Washington, Pennsylvania. “
A number of other analysts have also recently weighed in on the stock. Roth Capital upped their price target on shares of Madrigal Pharmaceuticals from $82.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, December 11th. Evercore ISI upped their price target on shares of Madrigal Pharmaceuticals from $65.00 to $140.00 and gave the stock an “outperform” rating in a research report on Thursday, December 7th. JMP Securities upped their price target on shares of Madrigal Pharmaceuticals from $63.00 to $125.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 6th. Finally, HC Wainwright upped their price target on shares of Madrigal Pharmaceuticals from $54.00 to $105.00 and gave the stock a “buy” rating in a research report on Wednesday, December 6th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Madrigal Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $129.00.
Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) traded up $8.16 during midday trading on Tuesday, hitting $107.00. 253,562 shares of the stock traded hands, compared to its average volume of 285,117. Madrigal Pharmaceuticals has a one year low of $13.09 and a one year high of $109.97. The stock has a market cap of $1,500.00, a PE ratio of -43.50 and a beta of 0.80.
Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.11. analysts predict that Madrigal Pharmaceuticals will post -2.57 earnings per share for the current year.
A number of institutional investors have recently made changes to their positions in MDGL. Schwab Charles Investment Management Inc. purchased a new stake in Madrigal Pharmaceuticals during the 2nd quarter worth $225,000. Bank of New York Mellon Corp purchased a new position in Madrigal Pharmaceuticals in the 2nd quarter valued at about $179,000. TIAA CREF Investment Management LLC purchased a new position in Madrigal Pharmaceuticals in the 2nd quarter valued at about $120,000. New York State Common Retirement Fund purchased a new position in Madrigal Pharmaceuticals in the 2nd quarter valued at about $109,000. Finally, Citigroup Inc. purchased a new position in Madrigal Pharmaceuticals in the 2nd quarter valued at about $185,000. 19.10% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/01/13/madrigal-pharmaceuticals-mdgl-rating-lowered-to-hold-at-zacks-investment-research.html.
Madrigal Pharmaceuticals Company Profile
Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.